MEDGm vs MyStart Health

Strengths

• +Names four dispensing pharmacies with street addresses and phone numbers
• +States its compounding class — produced in state-licensed 503A or FDA-registered facilities — rather than leaving it unsaid
• +Coverage is 50 states plus the District of Columbia and the intake's own state selector agrees with the Terms, which is rarer than it should be
• +Refills and shipping are described as included, with no separate shipping line at checkout
• +Prices an oral semaglutide lane alongside both injections

Where it loses points

• –No price is visible until a sixteen-screen quiz ending in name, email and phone number has been completed
• –$179 and $279 are first-month rates produced by an auto-applied coupon; the standing month-to-month rates are $299 and $399
• –The treatments FAQ says “your price never increases, even as your dose goes up” on a plan whose price increases at the first renewal
• –The twelve-month bundle auto-renews for another full upfront charge of $2,028 or $3,228, billed up to ten days early, and nothing is refundable once taken
• –The funnel prints “prescription plan approved” and a 100% success probability before any payment and before a clinician has seen the intake, beside a twenty-minute timer that resets on reload
• –Zepbound, Wegovy and Ozempic have cards on the GLP-1 page and all six links lead to the quiz; the post-intake funnel contains none of those names
• –No principal place of business is published — only a Delaware state of formation
• –No clinician is named and no NPI appears anywhere; the site names professional entities only

FDAWarning letter issued to Matthew Stern, CEO MyStart Health LLC. in September 2025. See the FDA warning-letter database.

Strengths

• +Price Lock Guarantee — your $299 base rate doesn't rise as your dose escalates
• +Fast onboarding: roughly 5-minute intake, 24-hour prescription turnaround, 2–4 day shipping
• +24/7 care team access with unlimited clinician messaging included
• +LegitScript certified
• +Clear Section 503A compounding disclosure on every landing page

Where it loses points

• –Not BBB accredited — C+ rating with 10 complaints, mostly shipping delays and support access
• –Compounded only — no FDA-approved Ozempic, Wegovy, Zepbound, or Mounjaro
• –Markets oral tirzepatide, but no FDA-approved oral tirzepatide exists
• –Very new company (incorporated May 2024) with a limited track record
• –FDA issued Matthew Stern, CEO MyStart Health LLC. a warning letter in September 2025; the letter is public in FDA's warning-letter database